EGFR and non-small cell lung carcinoma: These preclinical data support further evaluation of OB-001 as a strategy to enhance the CNS efficacy of osimertinib in EGFR-mutant NSCLC.<h4>Significance</h4>Blood-brain barrier (BBB) efflux limits osimertinib brain exposure.